InvestorsHub Logo
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Wednesday, 07/11/2018 11:23:18 AM

Wednesday, July 11, 2018 11:23:18 AM

Post# of 1162
FDA approves Opdivo/Yervoy in second-line CRC with MSI-H or dMMR:

https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibbs-opdivo-nivolumab-low-dose-yervoy-ipilimu?linkId=54128866

This is an accelerated approval based on ORR and duration of response in a single-arm trial.

Keytruda monotherapy is approved for this indication in the first-line setting (#msg-131597556).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News